I am a
Home I AM A Search Login

Papers of the Week

2020 Aug 28

Cochrane Database Syst Rev


Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.


Murray A, Nguyen TM, Parker CE, Feagan BG, MacDonald JK
Cochrane Database Syst Rev. 2020 Aug 28; 8:CD000544.
PMID: 32856298.


Oral 5-aminosalicylic acid (5-ASA; also known as mesalazine or mesalamine) preparations were intended to avoid the adverse effects of sulfasalazine (SASP) while maintaining its therapeutic benefits. In an earlier version of this review, we found that 5-ASA drugs were more effective than placebo for maintenance of remission of ulcerative colitis (UC), but had a significant therapeutic inferiority relative to SASP. In this version, we have rerun the search to bring the review up to date.